by Taylor Abarca | May 3, 2017 | Research
Patients with castration resistant prostate cancer (CRPC) usually have a poor prognosis. In part, this is due to the cancer’s ability to resist anti-androgen therapy. A University of Colorado Cancer Center study published today in Oncotarget shows that combining a...
by Garth Sundem | Apr 5, 2017 | Latest News, Research
Patients with metastatic prostate cancer whose PSA levels remain high despite initial hormone treatments have historically had poor prognosis, with survival typically in the 1-2 year range. Results of a 40-person clinical trial published in JAMA Oncology show that 13...
by Taylor Abarca | Feb 8, 2017 | Latest News
Brandon Bernard, MD, a medical oncologist, is joining University of Colorado Cancer Center’s elite team of physician/scientists treating and researching genitourinary cancers like prostate cancer. Bernard has big plans during his time at the Cancer Center. In...
by Garth Sundem | Dec 8, 2016 | Latest News, Research
Starting in 1993 and ending in 2001, ten academic medical centers in the United States screened 76,685 men and 78,216 women for prostate, lung, colorectal and ovarian cancers. The question was whether yearly screening could catch cancers early and thus decrease...
by Garth Sundem | Nov 15, 2016 | Featured, Latest News, Research
Knowing the likely course of cancer can influence treatment decisions. Now a new prediction model published today in Lancet Oncology offers a more accurate prognosis for a patient’s metastatic castration-resistant prostate cancer. The approach was as novel as...
